Clinical Trial

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this study is to establish the safety and tolerability of pembrolizumab when administered in combination with either of two chemotherapy regimens (weekly paclitaxel or capecitabine) in unresectable/metastatic triple negative breast cancer (MTNBC) patients.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2016-04-05; most recent amendment 2026-04-07.
Status change: Recruiting → Active, Not Recruiting 2019-10-25
Status change: Not Yet Recruiting → Recruiting 2016-05-18
Trial Details
NCT Number NCT02734290
Lead Sponsor Providence Health & Services
Collaborators: Merck Sharp & Dohme LLC
Conditions Triple Negative Breast Cancer
Enrollment 29 participants
Start Date 2016-02-23
Primary Completion 2019-08-21 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-24